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Proteins and amino acids are widely considered to be subcomponents in nutritional support. However, proteins
and amino acids are fundamental to recovery and survival, not only for their ability to preserve active tissue
(protein) mass but also for a variety of other functions. Understanding the optimal amount of protein intake during
nutritional support is therefore fundamental to appropriate clinical care. Although the body adapts in some ways to
starvation, metabolic stress in patients causes increased protein turnover and loss of lean body mass. In this review,
we present the growing scientific evidence showing the importance of protein and amino acid provision in
nutritional support and their impact on preservation of muscle mass and patient outcomes. Studies identifying
optimal dosing for proteins and amino acids are not currently available. We discuss the challenges physicians face
in administering the optimal amount of protein and amino acids. We present protein-related nutrition concepts,
including adaptation to starvation and stress, anabolic resistance, and potential adverse effects of amino acid
provision. We describe the methods for assessment of protein status, and outcomes related to protein nutritional
support for critically ill patients. The identification of a protein target for individual critically ill patients is crucial for
outcomes, particularly for specific subpopulations, such as obese and older patients. Additional research is urgently
needed to address these issues.Introduction
Proteins and amino acids (AAs) play a major role in the
maintenance of body homeostasis and their metabolism
in critically ill patients has been intensively researched
over the past 40 years. In contrast, few studies of opti-
mal protein or AA intake have been conducted in pa-
tients requiring nutritional support [1]. This review
highlights the importance of protein in nutritional sup-
port for critically ill patients and provides the rationale
for conducting additional, much-needed studies to im-
prove protein and AA nutritional support.
In this review, protein intake refers to enteral nutri-
tion, AA intake refers to parenteral nutrition (PN), and
nitrogen (N) generally refers to metabolism and overall
N balance. The administration of AA at pharmacological* Correspondence: p.weijs@vumc.nl
1Department of Nutrition and Dietetics, Internal Medicine, VU University
Medical Center Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam,
the Netherlands
2Department of Intensive Care Medicine, VU University Medical Center
Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands
Full list of author information is available at the end of the article
© 2014 Weijs et al.; licensee BioMed Central L
months following its publication. After this time,
(http://creativecommons.org/licenses/by/4.0), wh
the original work is properly credited. The Creati
publicdomain/zero/1.0) applies to the data madlevels (for example, glutamine, arginine) is not discussed
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have been published recently on this topic [2-4].A historical perspective
Protein nutrition, provided by intravenous AA infusion,
has been used for more than 70 years [5] and it was be-
lieved that insufficient intravenous energy provision pre-
vented the efficient use of these AAs [6]. Infusion of
hypertonic glucose through a central venous catheter
was first described in 1955 [7] and indwelling catheters,
hypertonic glucose, protein hydrolysates, and other nu-
trients were used successfully on a limited clinical basis
over the next 10 years. Dudrick and colleagues demon-
strated that all nutrients necessary for growth could be
provided by intravenous feeding [8]. Over the following
decade, research focused on accurately defining nutri-
tional requirements, particularly for micronutrients, and
on the technical aspects of adequate intravenous delivery
of energy or AAs. As it became technically possible to de-
liver more nonprotein energy intravenously, the problemtd. The licensee has exclusive rights to distribute this article, in any medium, for 12
the article is available under the terms of the Creative Commons Attribution License
ich permits unrestricted use, distribution, and reproduction in any medium, provided
ve Commons Public Domain Dedication waiver (http://creativecommons.org/
e available in this article, unless otherwise stated.
Weijs et al. Critical Care 2014, 18:591 Page 2 of 13
http://ccforum.com/content/18/6/591of overfeeding arose. One adverse effect of overfeeding is
the deposition of fat in the liver, particularly in patients re-
ceiving total PN for reversal of the catabolic response to
critical illness [9,10].
The progressive and rapid loss of body mass and muscle
well known to occur in patients with critical illness was
termed hypermetabolism. The view at the time was that
critically ill patients have very high energy expenditure
and therefore require high-energy nutrition. Septic auto-
cannibalism was a term used to describe the loss of
muscle mass that does not benefit from increasing AA
provision above minimum requirements [11]. Therefore,
through the 1970s, researchers focused on ensuring that
energy intake exceeded expenditure, rather than on targets
for adequate protein intake [9]. Later, when enteral nutri-
tion became a viable option in critically ill patients, nutri-
tional interventions continued to focus on meeting energy
requirements. When recommendations for protein or AA
intake were given, they were generally expressed as a
function of energy intake. For example, in the 1990s the
American College of Chest Physicians recommended that,
for patients in ICUs, ‘15-20% of the total calories adminis-
tered per day can be given as protein or amino acids’ [10].
However, the guidelines provided neither the rationale nor
the scientific basis for this recommendation.
As we move further into the 21st century, our under-
standing of the importance of protein nutrition in critic-
ally ill patients is increasing. However, further research
is needed to better define the optimal intake of protein,
in the same way that total energy requirements are de-
fined at present.
Important protein-related concepts: a metabolic
perspective
Adaptation to starvation
In a healthy person, an inadequate supply of protein and
energy (that is, semi-starvation or full starvation) results
in protein energy malnutrition. Semi-starvation induces
metabolic adaptations in protein metabolism that limit
the rate at which lean mass is lost [12,13]. When energy
supplies fall short in a healthy person, physical activity is
reduced to maintain an energy balance. However, a
decrease in activity to some extent counteracts the
adaptations that limit the loss of lean mass. During
starvation, heart and lung muscle may initially be pref-
erentially spared and a disproportionate amount of
peripheral skeletal muscle is lost. Ultimately, however,
the essential muscle mass of vital organs will also be
reduced and, in combination with underused periph-
eral skeletal muscle, results in muscle weakness and
functional disability [12,13]. These adaptive responses
may be considered successful because they allow
humans to survive limited periods of starvation. How-
ever, if protein and energy provisions continue toremain inadequate, essential bodily functions, such as
the immune system, will be adversely affected. Im-
paired immune function may lead to an increased risk
of infections, which in starvation is often seen as a dir-
ect cause of death. Starvation has serious implications
for a healthy individual, which are even more pro-
nounced in critically ill patients, especially those with a
low body mass index [14].
Adaptation of protein and amino acid metabolism under
conditions of stress
Humans have developed survival systems during meta-
bolic stress, such as AA use for gluconeogenesis and
acute phase protein reactions, increased protein turn-
over, and adapted regulation by catabolic hormones. In
stress situations, the priority of the metabolic response
is to provide energy to both the brain and injured tissues
to promote healing [15,16]. Humans have very limited
glucose stores and cannot synthesize glucose from fat.
Therefore, in the absence of glucose intake, glucose is
synthesized from gluconeogenic AA, lactate, and pyru-
vate. In the starving healthy individual, glucose infusion
inhibits gluconeogenesis. In stress situations, however,
gluconeogenesis is not readily reversed by glucose infu-
sion, implying that N may be lost through ureagenesis.
The pool of free essential AAs is very small, with most
generated from net proteolysis, occurring particularly
within muscles [17]. In critically ill patients, in parallel
with the severity of the injury, increases in proinflam-
matory cytokines, glucocorticoids, and oxidative stress
reinforce the effect of catabolic hormones, and contrib-
ute to insulin resistance and muscle wasting [18,19]. In-
sulin resistance is common in critically ill patients [20],
and contributes to net muscle protein catabolism and
liver gluconeogenesis (see Anabolic resistance).
In critically ill patients, a fraction of the essential AAs
arising from protein breakdown is oxidized in muscle at
an increased rate, in particular branched-chain AAs, while
another fraction is released into the blood at an acceler-
ated rate and rapidly cleared by organs such as the liver.
In general, there is a unidirectional flux of all AAs from
muscle to liver, controlled by hormones. Cortisol pro-
motes net muscle proteolysis and AA release, while gluca-
gon promotes AA uptake by the liver and AA use in
gluconeogenesis [21]. In the liver there is a large increase
in AA uptake for gluconeogenesis and for protein synthe-
sis, including the synthesis of acute phase proteins [22,23].
Some AAs are also taken up selectively by other tissues
for specific purposes. For example, glutamine is taken up
by the kidneys (to sustain ammoniagenesis and counteract
acidosis), by fibroblasts and enterocytes (for healing), and
by immune cells (for replication and action) [24].
As long as these processes remain adaptive, plasma
AA levels remain stable and in balance. However, when
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too long, the balanced AA profile in plasma is disrupted,
resulting in abnormal AA concentrations (both higher and
lower levels than normal) [25-27]. In particular, plasma
glutamine concentrations have been associated with un-
favorable outcomes in critically ill patients [28,29].
Under stress conditions, the various alterations in protein
metabolism are reflected by an increase in whole-body
protein turnover [30,31] and an increase in AA oxidation
and N loss. Since all proteins within the body have specific
functions (see Table 1), they cannot be considered a form
of AA storage, highlighting the importance of exogenous
sources of protein or AA by nutritional support.
Muscle proteins
Muscle proteins are in a constant state of turnover and
the balance between the rates of protein breakdown and
synthesis determines whether there is a net gain (anabol-
ism) or a net loss (catabolism, wasting). A number of cir-
cumstances (for example, burn injury, trauma complicated
with sepsis, head trauma) result in loss of muscle mass
driven by an accelerated rate of protein breakdown [32].
The increased release of AAs from protein breakdown
provides a stimulus for accelerated muscle protein
synthesis [33]. Protein synthesis cannot match the in-
creased rate of muscle protein breakdown, although
protein synthesis rates do vary significantly from pa-
tient to patient [22,34].
In a stress situation, the catabolic loss of muscle can
be avoided only if the uptake of AAs from the blood is
increased either by intravenous infusion or the digestion
of enterally administered proteins, peptides, or AAs.
These sources of AA may then stimulate protein synthe-
sis to offset the accelerated rate of protein breakdown
and AA oxidation [22,35,36].
Anabolic resistance
Anabolic resistance refers to the state in which a patient
is resistant to the normal stimulatory effect of AAs on
muscle protein synthesis. This is common in older pa-
tients and may contribute to the estimated 1.4 to 2.5%Table 1 Functions of proteins
• Proteins are the major components of muscles, required for muscle dynam
• Enzymes are proteins. Therefore, proteins are essential for intermediary me
• Some proteins are involved in specific immunity (that is, immunoglobulin
• Proteins contribute to the architecture and structure of organs and tissues
example, in bone and skin
• Proteins secreted into the blood by the liver are carriers of lipid-soluble m
(for example, retinol binding protein for vitamin A), nutrients (for example
• Proteins in the blood, especially albumin, are involved in the control of on
• Proteins contribute physiologically to energy expenditure (12 to 15% of to
amino acids following proteolysis. This may occur directly (for example, br
(gluconeogenesis) or ketone body (ketogenesis))muscle loss per year in that group [37]. Anabolic resist-
ance is also frequently observed in critically ill patients
[38], in patients on bed rest, or in people exposed to
weightless environments (such as in space) [39]. Three
main factors explain anabolic resistance: splanchnic se-
questration of AAs following feeding [40,41], which de-
creases the AAs available to muscles; insulin resistance,
which limits AA uptake into muscles [42] and hinders
the maintenance of muscle protein [39]; and blunted re-
sponses to AAs with anabolic properties, such as the
essential AA leucine [19,43]. The older patients require a
higher intake of essential AAs compared with the young
to generate the same acute response [42]. However,
there is a lack of data on AA requirements in older pa-
tients in the ICU; these requirements warrant urgent re-
search, since the number of older patients in the ICU is
likely to increase in parallel with that of the general
population. Muscle protein anabolism can be optimized
in otherwise healthy individuals by a combination of ad-
equate protein or AA intake, combined with exercise
and insulin [44].
Anabolic resistance is also driven by insensitivity to
the normal anabolic action of leucine. In stressed pa-
tients, the level of muscle-free leucine is higher than in
patients without stress [25,45,46]. Experimental models
show that leucine stimulates protein synthesis via signal-
ing through the mammalian target of rapamycin system
[47]. Leucine and insulin share common pathways for
activating protein synthesis, suggesting that signal trans-
duction is impaired somewhere within the mammalian
target of rapamycin pathway. However, there may be dif-
ferences in the acute and prolonged effects of leucine
supplementation [48]. Research into the role of leucine
in different clinical settings has potential implications
for the treatment of muscle loss in metabolically stressed
patients.
Interaction of protein with nonprotein energy
The efficiency of protein intake in stimulating protein
synthesis is dependent to some extent on the level and
nature of the nonprotein energy intake. Many nutritionalics and function
tabolism and energy production. Similarly, all cell carriers are proteins
s) and in nonspecific immunity (for example, opsonins)
. A typical example is collagen, which has a major architectural role, for
olecules: hormones (for example, transthyretin for thyroxin), vitamins
, albumin for free fatty acids and tryptophan), and a number of drugs
cotic (colloid osmotic) pressure
tal daily expenditure) in the postabsorptive state, through release of
anched-chain amino acids in the muscles) or indirectly (through glucose
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support are derived from requirements for healthy indi-
viduals. It has been known for almost 100 years that the
amount of protein intake required to maintain N balance
in healthy individuals is a function of the amount of
concomitant energy intake [49]. Meeting energy require-
ments is a major goal of appropriate nutrition support.
However, delivering excessive energy to severely stressed
patients usually fails to enhance the retention of body
protein [50] and often causes adverse effects, such as se-
vere fatty infiltration of the liver [51]. In a catabolic
state, loss of lean body mass (LBM) often cannot be en-
tirely prevented by nutrition support.
The realistic aim of nutrition support is to blunt the
loss of LBM, and the goal should be to supply the
amount and nature of protein or AA intake that can
maximally stimulate protein synthesis [52]. Even in the
insulin-resistant state, AAs can stimulate, to some ex-
tent, muscle protein synthesis [53]. The provision of ad-
equate, but not excessive, nonprotein energy may
provide some benefit to stressed patients. The potential
for detrimental effects is considerable, however, and care
should be taken to avoid supplying nonprotein energy in
excess of energy expenditure.
Amino acid transport
The first step in AA processing is cellular uptake, and
many different AA transporters occur in different cell
types [54]. There are also transporters that cycle certain
AAs between the cytosol and mitochondria. For ex-
ample, the ureagenesis pathway transports ornithine
from the cytosol to mitcohondria and citrulline from
mitochondria to the cytosol [55]. One transporter may
take up several AAs, and a single AA may have more
than one transporter. Consequently, some AAs compete
with each other for cellular uptake and the provision of
an imbalanced AA solution may lead to an inappropriate
cellular response. The pharmacokinetic properties of any
new AA formula should therefore be tested, as well as
the quantity and quality of the AA formulation.
Potential adverse effects of amino acid provision
Most AAs are precursors of neuromediators or of false
neuromediators (that is, AAs or metabolites able to bind
to neuroreceptors, eliciting or blocking the messages of
the true mediators). Administration of large nonphysio-
logic amounts of AA may lead to seizures and brain
damage [56]. Defining an upper limit of safe intake for
each AA is therefore of utmost importance [57]. This
has been achieved for leucine, which has an upper limit
of safe intake of 0.53 g/kg body weight/day in healthy
subjects [58]. Of note, this level of leucine intake is
well above the normal requirement. There is currently
no recommendation concerning the safety of leucineadministration in patients, due to the lack of dose-ranging
studies. Tolerability varies from one AA to another [59].
Some AAs appear extremely safe even when given in the
15 to 30 g/day range (for example, glutamine, citrulline)
[24], at least in the short term [60], whereas tolerance to
other AAs (for example, methionine) seems limited [61].
At present, the safety of arginine in ICU patients is a topic
of some debate [62,63].
Methods for assessment of protein status
Nitrogen balance
The N balance is commonly used as the basis for esti-
mating protein requirements in healthy individuals
[64,65] and in patients [66-68]. The N balance becomes
negative when intake falls short of the minimum protein
requirement, leading to loss of LBM. In an otherwise
healthy person, however, a chronic low-protein diet may
lead to adaptation to a stable overall N balance [69].
Estimation of both N intake and N loss presents chal-
lenges that must be considered carefully [70]. While N
intake can be accurately measured in patients supported
with total enteral nutrition or PN, the assessment of oral
dietary protein intake is extremely difficult in clinical
practice. Measuring N loss is also problematic, because
it is not easy to collect complete 24-hour urine samples,
especially in patients with large fecal or urinary output
(for example, those with burns or a bone marrow trans-
plant) [71]. In the critically ill patient, total body N loss
from urinary urea content underestimates N loss as
these patients have an increase in ammonia loss not
accounted for in N calculations from urinary urea
[72,73]. Therefore, in ICU patients, total urinary N loss
should be measured directly rather than estimated from
urinary urea. However, even direct measurements of urin-
ary loss do not reflect the total loss, as they do not include
N loss from diarrhea, fistulas, or draining wounds [71].
A positive N balance is not synonymous with im-
proved protein balance, as the N balance after admi-
nistration of a load of a single AA may simply reflect
cellular accumulation of the free AA [74]. In addition,
for critically ill patients, intravenous administration of
protein-containing blood products confounds N-balance
assessments. Nevertheless, measurement of urinary N
loss and calculation of N balance remains the most com-
monly used biomarker to assess protein accretion or loss
in ICU patients. Additional information on plasma and
urinary levels of conventional markers of protein status
is provided in Table 2.
Assessment of qualitative and quantitative amino acid
requirements
AA requirements may be assessed by simple pharmaco-
kinetic studies. The balance between the requirement
for and intake of an AA can be assessed by measuring
Table 2 Plasma and urinary levels of conventional markers of protein status
Subject of measurement Rationale Usage
Plasma protein levels: albumin,
transthyretin (formerly called
prealbumin), and retinol binding
protein
These proteins are selectively synthesized by the liver.
Therefore, it is generally believed that their rate of
synthesis parallels the supply of amino acids. In the
case of inflammation, plasma levels of these proteins
do not indicate nutritional status
Transthyretin measurements can be used to assess
the efficacy of nutrition support [75], while albumin
measurements can be used to assess the risk of
complications associated with malnutrition. When
used for this purpose, albumin may be used alone
[76] or, ideally, as an index to be considered in
combination with variations in body weight over time
(nutritional risk index [77] in adults, geriatric nutritional
risk index [78] in geriatric patients)
Urinary 3-methylhistidine (3MH) 3MH is derived from histidine with a post-
transcriptional methylation at position 3. This amino
acid is present mainly in myofibrillar proteins and, to a
smaller extent, in intestinal smooth muscles. Following
proteolysis, released 3MH is not reincorporated into
proteins since there is no codon for this amino acid.
Instead, 3MH is further eliminated into urine
There is a correlation between the 24-hour excretion
of 3MH and myofibrillar proteolysis. Since the former
will be dependent upon muscle mass, 3MH excretion
must be expressed as a ratio to urinary creatinine.
It has been clearly demonstrated that muscle myofibrillar
proteins account for the entire increase in 3MH excretion
during hypercatabolic states [79]. In chronic malnutrition,
urinary 3MH is low due to restriction adaptation, and
improvement in the nutritional state leads to an increase
of this parameter because elevated protein synthesis
leads to an increase in proteolysis
Plasma phenylalanine Phenylalanine is mainly catabolized in the liver, and
not in the muscle. The arteriovenous difference in
phenylalanine concentration is a marker of muscle
proteolysis. Unfortunately, arterial puncture is an
invasive procedure, and is associated with technical
problems that complicate the use of this marker. In
addition, interpretation of the data requires that blood
flow is measured simultaneously. Alternatively, plasma
phenylalanine can be measured as a marker of
protein turnover. Some authors have suggested
measuring the phenylalanine:tyrosine ratio for this
purpose
It has been shown [80] that plasma phenylalanine
correlates well with nitrogen balance in burn patients.
At present, there are insufficient data available to
recommend the use of plasma phenylalanine or of
the phenylalanine:tyrosine ratio as a reliable marker of
protein turnover
Plasma citrulline The amino acid citrulline is not included in proteins
and it is almost absent in food. In the general
circulation, most citrulline is formed in enterocytes
and is mostly catabolized in the kidneys [81]. Of note,
citrulline in the liver is strictly compartmentalized
within periportal hepatocytes [61] and the liver
neither takes citrulline up nor releases it, except in
patients with liver cancer [82]
Following the pioneering work by Crenn and
colleagues [83] in patients with short bowel
syndrome, plasma citrulline has been validated as a
marker of gut functional mass in a number of clinical
situations (see [84] for a recent review)
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state and at various times during AA administration.
Several studies, summarized in 2003 [85], indicate that
during continuous parenteral administration of AAs
there is a sharp increase in AA levels followed by a plat-
eau that lasts several hours. The level of the plateau
appears to be related to the rate of infusion of each
AA [85]. It is therefore possible to construct a one-
compartment model with first-order elimination kinetics
[86] to study the relationship between the increase in
plasma AA concentration and the rate of infusion for
any AA. This model was tested in surgical ICU patients.
In ICU patients receiving a more individualized AA
solution, based on the dynamic test described above, ab-
normal changes in AA levels were almost eliminated,
while they persisted in the control group. The 5-day N
balance was significantly improved with this individual-
ized kinetic approach in the surgical ICU study [87].These studies suggest that, in the future, AA solutions
for PN should be formulated for specific disease states.
However, the concepts demonstrated by this kinetic ap-
proach will need to be validated by additional prospect-
ive clinical studies.
Whole-body and muscle protein synthesis
Estimation of N balance is a black-box approach that
provides no information about underlying mechanisms,
such as variations of protein synthesis and breakdown at
the whole-body or tissue level. An alternative approach
is to quantify protein needs and determine appropriate
protein provision by measuring protein synthesis in the
whole body and/or muscle.
AA tracers are commonly used in clinical research.
They are created by incorporating stable isotopes of car-
bon, hydrogen, or N into an AA to produce a uniquely
identifiable molecule. Labeled AAs can be administered
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metabolism of the more abundant form of the AA in the
body. Mass spectrometry analysis of the AA tracer in
blood or protein enables the calculation of whole-body
protein synthesis and whole-body protein breakdown.
All proteins in the body, including muscle, will incorpor-
ate the labeled AA at rates that reflect the fractional syn-
thetic rate of the protein [88].
The muscle fractional synthetic rate reflects only the
synthetic rate of muscle protein. The net gain or loss of
protein is determined by the balance between its rate of
synthesis and its rate of breakdown. However, the
muscle fractional protein breakdown rate is not com-
monly assessed because it requires a more complicated
experimental protocol, additional blood sampling, and
complex calculations, especially during feeding [89]. One
approach to calculating muscle protein synthesis and
breakdown is to measure the balance of specific AAs
across the leg or arm [90]. This requires arterial and
venous catheterization and measurement of tissue blood
flow. When combined with muscle tissue biopsy data,
the rates of muscle protein synthesis, breakdown, and
net balance can be calculated. In addition, the rate of
AA uptake and release into blood can be measured [90].
Differences in limb blood flow may alter the measured
arteriovenous balance, however, limiting the applicability
of this technique.
In a research setting, whole-body protein synthesis
and breakdown can also be measured in response to
protein feeding or PN. One commonly used approach is
the addition of phenylalanine/leucine to a meal, together
with an infusion of labeled tyrosine and phenylalanine,
followed by blood sampling [88]. An advantage of this
approach is that muscle biopsies are not required, and
frequent blood sampling enables calculations of both
synthesis and breakdown during protein or AA absorp-
tion. While tracer methods have been used to study the
acute response of whole-body or protein synthesis in
metabolically stressed patients, a systematic investigation
of protein synthesis and breakdown has not yet been
performed. An appropriately designed isotopic study
providing direct evidence for the protein needs of critic-
ally ill patients would be of great value.
Muscle mass and lean body mass
Measurement of LBM (that is, fat-free mass, including
extracellular fluid) over time should provide important
insights into an individual patient’s requirement for pro-
tein intake. However, attempts to measure LBM easily
and accurately at the bedside in the ICU have to date
been unsuccessful. It is important to determine which
body-compartment measurement best reflects the daily
amount of protein needed to maintain equilibrium. Total
body mass is not useful because the varying amounts offat mass are not relevant to protein metabolism. Also,
standard body weight or ideal body weight measure-
ments are not appropriate as they lead to imprecise esti-
mates in obese patients [91]. The most appropriate
compartments for determining protein requirements are
LBM and body cell mass (that is, the sum of all living
cells excluding extracellular fluid and bone mass). Both
of these compartments can be measured in clinical
practice using bioelectrical impedance analysis [92,93].
However, the overall precision of bioelectrical imped-
ance analysis may be reduced by variations in hydration
status. Dual-energy X-ray absorptiometry [94] can be
used to assess LBM, although dual-energy X-ray absorp-
tiometry scanners are not available in every hospital and
are not routinely used for critically ill patients.
Computed tomography (CT) may also be used to as-
sess LBM [95]. Specialized CT software has been used at
the third lumbar spine to determine the area of skeletal
muscle, as well as subcutaneous, intramuscular, and vis-
ceral adipose tissue. A lower LBM, as determined by CT
imaging at the third lumbar spine, is an adverse prog-
nostic factor in patients with pancreatic cancer and sar-
copenic obesity [96]. Recently, Moisey and colleagues
have demonstrated the prognostic value of LBM for
predicting mortality in critically ill, older, sarcopenic,
injured patients [97]. Weijs and colleagues confirmed
these findings in a population with a much broader age
range and mixed diagnoses [98].
Since CT scanning technology exists in most hospitals
and many hospital patients undergo an abdominal CT
scan, analysis of skeletal muscle in a single CT slice
could be carried out routinely. However, routine use of
CT scanning for patients in the ICU remains a difficult
logistical problem. Bedside ultrasound imaging could
also be used to measure muscle thickness, avoiding the
potential issues associated with radiation doses from CT
scans. However, additional research is needed to develop
a reliable and sensitive technique for assessing LBM [99]
and these methods require validation in this setting [68].
The report of muscle wasting in ICU patients by
Puthucheary and colleagues highlights the importance of
monitoring [34]. Recent studies have provided preliminary
data showing a statistical relationship between muscle
wasting and protein intake [100,101]. However, muscle
mass varies too slowly to be used as a day-to-day tool for
fine-tuning protein intake.
Protein nutrition support and outcome in
critically ill patients
Muscle wasting and functional impairment
As outlined above, body protein from functional tissues
is catabolized during critical illness and may culminate
in a clinically significant loss of muscle mass [34]. The
extent of muscle mass loss may impact the ultimate
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mass often leads to impaired functioning, which hinders
activities such as weaning from the ventilator and muscle
function recovery. These adverse outcomes can result
in increased nosocomial infection, such as pneumonia,
bacteremia, and wound infection, leading to a renewed
state of increased catabolism. This vicious cycle is associ-
ated with poor patient outcomes. Functional disability
may be long term and may never fully return to normal
levels [102,103]. The increased efflux of AAs from cata-
bolic muscle also places a metabolic burden on the liver.
Therefore, in highly catabolic states of muscle protein
breakdown, it is clinically important that the liver clear-
ance of AAs for protein synthesis and other metabolic
functions remains intact [104,105].
Pharmacological therapy has the potential to work in
concert with dietary protein to ameliorate the rate of
muscle loss in critically ill patients. Among others, insu-
lin [106], propranolol [107], and testosterone [108] have
all been used successfully in seriously burned patients in
conjunction with adequate nutritional support to lessen
the extent of muscle protein loss. Pharmacological doses
of growth hormone actually stimulate muscle protein
synthesis in the critically ill [109]. However, critically ill
patients treated with human growth hormone had a
higher mortality than untreated patients [110]. In other
words, blocking muscle protein breakdown is not recom-
mended if adequate nutritional support is not provided.
When feasible, the combination of adequate protein intake
with early exercise should be further investigated as a
means by which to improve both short-term and long-
term outcomes.
Level of protein nutrition support in critically ill patients
Current recommendations advise a protein intake level
in critically ill patients of more than 1.2 g/kg/day
[111-113]. Guidelines are based on results from studies
employing N balance and body composition techniques
in which protein intake exceeding 1.5 g/kg/day did not
provide any advantage [15,111-114]. However, based on
N balance data, authors of a systematic and critical re-
view suggested that a level of 2.0 to 2.5 g/kg/day may be
safe in many critically ill patients [68]. An observational
study of patients with head trauma demonstrated that a
higher N intake provided a better short-term N balance,
which at best supports the conclusion of safety [115].
Further, a recent study evaluating whole-body protein
turnover in adolescent patients given PN reported a pro-
tein balance advantage with a protein intake as high as
3.0 g/kg/day [116]. Whether this level of intake is appro-
priate for adults, however, is unknown. To date there
have been no outcome studies providing this level of
protein intake to critically ill patients. Even though rec-
ommended protein intakes for critically ill patients varywidely, there is a consistent recommendation that protein
intake should exceed the levels of 0.8 g/kg/day required by
normal, healthy individuals. At present, however, most
critically ill adults receive less than one-half of the recom-
mended protein intake (about 0.6 g/kg/day) [14].
Current evidence for protein nutrition support and outcome
There appears to be a lower than recommended protein
provision within the first week of patient admission
[14,68]. The clinical outcomes of several studies report-
ing protein intake in critically ill patients are summa-
rized in Table 3. Three large prospective trials [117-119]
investigating the use of evidence-based feeding guide-
lines in critically ill patients showed no significant differ-
ence in mortality, while nonrandomized studies indicate
a potential relationship between protein levels in nutri-
tion support and mortality [14,120-122]. These studies
suggest that protein supply is of major importance to
outcome in critically ill patients.
Randomized trials focusing only on energy provision
have not shown an impact on mortality [123-125,127,129].
Measured energy expenditure may be needed during tar-
geted feeding in the early phase of critical illness to avoid
overfeeding, and providing energy at 80 to 90% of energy
expenditure may be sufficient [130]. All of the large ran-
domized trials of early PN in critically ill patients have
used energy targets based on crude estimations of energy
requirements. Hypothetically, a high energy intake may in-
hibit autophagia, which may be a disadvantage for the crit-
ically ill patient, as this enables the accumulation of
cellular damage [131]. Whether this inhibition is restricted
to patients given PN or whether there is any clinical im-
pact from this observation remains an open question.
No randomized trials to date have adequately studied
protein provision in critically ill patients. New studies
using whole-body protein kinetics are needed to enable re-
assessment of the current recommendations [111-113].
Protein intake should be tailored to suit the patient, but
presently there is no recognized marker available to guide
individualized requirements.
In general, if enteral nutrition is possible, early provision
is advantageous to the patient [132] as demonstrated in
patients following trauma [133]. In patients with sepsis,
the evidence is less robust. However, this evidence as-
sumes enteral nutrition can be delivered to meet both pro-
tein and energy goals. Randomized trials have shown that
the use of early PN did not improve mortality [123,129].
However, these studies used low protein intake levels
compared with current guidelines.
Older studies using the endpoint of N balance or body
composition provide less relevant information during the
initial phase of critical illness due to the hemodynamic
instability of the patient [15,114]. Further research into
the relationship between whole-body (and organ) protein
Table 3 Studies reporting protein intake in critically ill patients
Citation Patient population Study design Clinical outcome: recovery, survival and length of
stay
Larsson and
colleagues [114]
Severely injured patients (burn or fracture of
more than two long bones). Randomized
during the first week of trauma (n = 39) to
five different amounts of N from 0 to
0.3 g/kg/day
Prospective
randomized study
Daily and cumulative N balance increased in the
groups with a N intake of up to 0.2 g/kg/day versus
the no N group (P <0.001)
Ishibashi and
colleagues [15]
Immediate post-trauma patients (n = 18) or
severely septic patients (n = 5) were divided
into three groups (A, B, and C) receiving 1.1,
1.5, and 1.9 g/kg FFMc/day protein
respectively
Retrospective
study
Average loss of total body protein was 1.2 kg. Loss of
body protein was greater in group A compared with
groups B (P = 0.013) and C (P = 0.023). Protein loss in
group B (1.5 g/kg FFMc/day), was half that of group
A (1.1 g/kg FFMc/day). Protein loss in groups B and C
was not different. An intake of 1.5 g/kg FFMc/day was
equivalent to 1.0 g/day/kg body weight measured at
the start of the study. Authors recommend the clinician
obtains information on pre-illness bodyweight and
prescribes 1.2 g/day/kg
Barr and
colleagues [118]
200 ICU patients (npo >48 hours after their
admission): 100 before implementation
of a nutritional management protocol,
100 afterwards
Prospective
evaluation
Risk of death was 56% lower in patients who received
EN (HR: 0.44, 95% CI: 0.24, 0.80, P = 0.007)
Martin and
colleagues [119]
499 ICU patients with an expected ICU stay
of at least 48 hours. Introduction of
evidence-based recommendations
Cluster-
randomized
controlled trial
Implementation of evidence-based recommendations
led to more days of EN (P = 0.042), shorter mean
hospital stay (P = 0.003) and a trend towards reduced
mortality (P =0.058). The mean ICU stay did not differ
significantly
Doig and
colleagues [117]
1,118 patients in the ICU >2 days.
Randomization to guideline or control
groups. Guideline ICUs used an
evidence-based guideline
Cluster-
randomized
controlled trial
Guideline ICU patients were fed earlier and reached
nutritional goals more often compared with control
subjects, but did not show significantly different hospital
discharge mortality (P = 0.75), hospital LOS (P = 0.97), or
ICU LOS (P = 0.42)
Alberda and
colleagues [14]
2,772 mechanically ventilated patients.
Prescribed and received energy was
reported
Observational
cohort study
Patients received only 56 to 64% of the nutritional
prescription for energy and 50 to 65% for protein.
Increased provision of energy and protein appear to
be associated with improved clinical outcomes,
particularly when BMI <25 or ≥35 kg/m2. A 1,000 kcal
increase is associated with improved mortality
(P = 0.014) and more ventilation-free days (P = 0.003)
Strack van
Schijndel and
colleagues [120]
243 sequential mixed medical-surgical
patients. Nutrition according to indirect
calorimetry and at least 1.2 g protein/kg/day
Prospective
observational
cohort study
Reaching nutritional goals improves ICU (P = 0.027)
and 28-day mortality (P = 0.005) and hospital survival
(P = 0.04) in female patients. When only energy goals
but not protein goals are met, ICU mortality is not
changed. No differences could be observed for male
patients
Casaer and
colleagues [123]
4,640 ICU patients: 2,312 patients received
PN within 48 hours after ICU admission,
2,328 patients received no PN before day 8
Randomized,
multicenter trial
Early provision of PN shows a higher complication
rate (26.2% vs 22.8% for ICU infections, P = 0.008),
longer mechanical ventilation time (9.7% longer,
P = 0.006) and renal replacement therapy (3 days’
longer, P = 0.008), and a longer mean hospital
duration (6.4% higher likelihood to discharge later,
P = 0.04), but no significant impact on mortality
Weijs and
colleagues [121]
886 mechanically ventilated patients;
stratified into three groups: reaching energy
and protein target; reaching energy target;
and reaching no target
Prospective
observational
cohort study
Reaching the energy and protein target is associated
with a 50% decrease in 28-day mortality. Reaching
only the energy target is not associated with an
improvement
Arabi and
colleagues [124]
240 ICU patients randomly assigned to
permissive underfeeding or target feeding
Randomized,
controlled trial
Permissive underfeeding may be associated with
lower mortality rates. Hospital mortality was lower in
the permissive feeding group (30.0% vs 42.5%;
relative risk: 0.71; 95% CI: 0.50, 0.99; P = 0.04).
However, 28-day all-cause mortality was not significantly
different between groups (18.3% vs 23.3%; relative risk:
0.79; 95% CI: 0.48, 1.29; P = 0.34)
Rice and
colleagues [125]
200 mechanically ventilated patients with
acute respiratory failure, expected to require
Randomized,
open-label study
Mortality to hospital discharge was 22.4% for trophic
vs 19.6% for full energy (P = 0.62). The trophic group
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Table 3 Studies reporting protein intake in critically ill patients (Continued)
mechanical ventilation for at least 72 hours
randomized to receive initial trophic (10 ml/
hour) or full-energy EN for the initial 6 days
showed a trend for less diarrhea in the first 6 days
(19% vs 24% of feeding days; P =0.08) and significantly
fewer episodes of elevated gastric residual volumes
(2% vs 8% of feeding days; P <0.001)
Singer and
colleagues [126]
130 patients expected to stay in
ICU >3 days. Randomization to EN with
a target determined by indirect calorimetry
(study group) or with 25 kcal/kg/day
(control group)
Prospective,
randomized,
controlled trial
Patients in the study group had a higher mean
energy (P =0.01) and protein intake (P =0.01) than the
control group. They also showed a trend towards
reduced mortality (32.3% vs 47.7%, P =0.058), but the
number of infectious complications were higher
(37 in the study vs 20 in the control group P =0.05)
Allingstrup and
colleagues [122]
113 ICU patients. Analyzed according to
provided amount of protein and AA
Prospective,
observational,
cohort study
In the low protein and AA provision group, the
Kaplan-Meier survival probability was 49% on day 10,
compared with 79% and 88% in the medium and
high protein and AA groups on day 10, respectively
Rice and
colleagues [127]
1,000 patients with acute lung injury
requiring mechanical ventilation.
Randomization to trophic or full enteral
feeding for the first 6 days
Randomized,
open-label,
multicenter trial
Initial trophic feeding did not improve 60-day mortality
(23.2% vs 22.2%, P =0.77) or infectious complications
(P =0.72, P =0.77, and P =0.24 for ventilator-associated
pneumonia, Clostridium difficile colitis and bacteremia,
respectively) compared with full enteral feeding
Heidegger and
colleagues [128]
ICU patients who had received less than 60% of
their energy target from EN, were expected
to stay >5 days, and to survive >7 days.
Randomization to SPN (n =153) or EN
(n =152). Protein administration was set to
1.2 g/kg ideal bodyweight/day during the study
Randomized
controlled trial
Mean energy delivery between days 4 and 8 was
higher for the SPN group (103% vs 77% of energy
target). Nosocomial infections, between days 9 and 28,
were more frequent in the EN group patients (38% vs
27%, P =0.0248). Overall nosocomial infections were not
different
AA, amino acids; BMI, body mass index; CI, confidence interval; EN, enteral nutrition; FFMc, corrected free fat mass; HR, hazard ratio; LOS, length of stay; N, nitrogen;
npo, nil by mouth; PN, parenteral nutrition; SPN, supplementary parenteral nutrition.
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iture is needed to characterize the status of protein metab-
olism in the early phase of critical illness before any
recommendations can be given [31,116,134].
Route of administration
For healthy individuals, the digestion of food demands
energy. However, in terms of N balance there is no dif-
ference between enteral and parenteral routes of ad-
ministration. For the critically ill patient the situation
is less clear, as it is difficult to characterize digestion
and absorption because patients are rarely in a steady
state long enough for N-balance studies to be com-
pleted. It should be recognized that AAs provided by
PN are free, hydrated molecules, and thus the actual
amount of protein substrate provided by parenteral AA
mixtures is usually overestimated, the amount pro-
vided being approximately 20% less than that provided
in food protein [68]. For enteral protein, the level of
absorption is a complicating factor because it may be
low and/or variable [71].
There is no option to store AAs in the body, so the
only way to handle excess protein intake is by AA oxida-
tion. Whether or not the oxidation of AA differs in rela-
tion to the route of administration is dependent upon
nutritional status, the amount of energy, protein, and
AA given, and the level of metabolic stress imposed on
the subject. Additional studies are needed in critically ill
patients to assess gastrointestinal uptake of AAs and tomeasure whole-body (and organ) protein turnover and
AA oxidation for different levels of intake [31,116,134].
Conclusions
Nutrition support in the critically ill has to date fo-
cused on adequate provision of energy to the patient.
Protein and AA provision has been dealt with as a sub-
component of energy supply. However, proteins and
AAs are fundamental to recovery and survival, not only
to preserve active tissue (protein) mass but also to
maintain a variety of other essential functions. The
scientific recognition of the importance of protein is
growing [68], and although optimal protein dosing
studies are not available, expert opinion supports ad-
ministering in excess of 1.2 g/kg/day [121,122,130].
The use of one fixed protein-to-energy ratio to achieve
both energy intake and protein intake targets often re-
sults in protein underfeeding or energy overfeeding. A
mixed approach with a range of enteral or parenteral
formulas may therefore help to balance protein and en-
ergy targeted feeding [121,130,135,136]. The identifica-
tion of a target for protein provision for individual
patients is a crucial step in recognizing the key role of
protein in nutrition support, especially for obese and
older patients (with low muscle mass) who are seen in
increasing numbers in the ICU. Further research is ur-
gently needed to assess the specific quantitative and
qualitative requirements of these patient subgroups.
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